While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. In today's biomarker-driven landscape, it is more important ...

In a recent review published in the journal Cell, a group of authors established a comprehensive framework for the terminology, characterization, and validation of aging biomarkers to facilitate their ...

IPF is a life-threatening lung disease with no known cause. Over time, the lungs become scarred, making it harder to breathe. More than 250,000 Americans are living with IPF and other interstitial ...

In follow-up to the Forum on Neuroscience and Nervous System Disorders' March 2023 workshop on Multimodal Biomarker for Central Nervous System Disorders: Development, Integration and Clinical Utility, ...

SAN DIEGO & TOKYO & MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...